{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:04:19Z","timestamp":1784642659884,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Association Neurofibromatoses et von recklinghausen","award":["45500euros"],"award-info":[{"award-number":["45500euros"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00223-021-00807-6","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T19:51:05Z","timestamp":1612900265000},"page":"738-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France"],"prefix":"10.1007","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-3150","authenticated-orcid":false,"given":"Maud","family":"Jalabert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Ferkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Souberbielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Mageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Guignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"issue":"3","key":"807_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","volume":"135","author":"E Uusitalo","year":"2015","unstructured":"Uusitalo E, Lepp\u00e4virta J, Koffert A, Suominen S, Vahtera J, Vahlberg T et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Investig Dermatol 135(3):904\u2013906","journal-title":"J Investig Dermatol"},{"issue":"8","key":"807_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13(8):834\u2013843","journal-title":"Lancet Neurol"},{"issue":"3","key":"807_CR3","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"23","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primer 23(3):17004","journal-title":"Nat Rev Dis Primer"},{"key":"807_CR4","unstructured":"The National Institutes of Health (NIH) Consensus Development Program: neurofibromatosis [Internet]. [cited 2018 Apr 17]. https:\/\/consensus.nih.gov\/1987\/1987Neurofibramatosis064html.htm"},{"issue":"3","key":"807_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.revmed.2004.06.011","volume":"26","author":"S Pinson","year":"2005","unstructured":"Pinson S, Wolkenstein P (2005) Neurofibromatosis type 1 or Von Recklinghausen\u2019s disease. Rev Med Interne 26(3):196\u2013215","journal-title":"Rev Med Interne"},{"issue":"8","key":"807_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.6061\/clinics\/2012(08)18","volume":"67","author":"KSG Cunha","year":"2012","unstructured":"Cunha KSG, Caruso AC, de Faria PAS, da Silva LE, Pires ARC, Geller M et al (2012) Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival. Clinics 67(8):963\u2013968","journal-title":"Clinics"},{"issue":"2","key":"807_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/archderm.139.2.187","volume":"139","author":"K Khosrotehrani","year":"2003","unstructured":"Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P (2003) Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 139(2):187\u2013191","journal-title":"Arch Dermatol"},{"issue":"2","key":"807_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1515\/jpem-2016-0092","volume":"30","author":"HG Poyrazo\u011flu","year":"2017","unstructured":"Poyrazo\u011flu HG, Ba\u015f VN, Arslan A, Bastug F, Canpolat M, Per H et al (2017) Bone mineral density and bone metabolic markers\u2019 status in children with neurofibromatosis type 1. J Pediatr Endocrinol Metab 30(2):175\u2013180","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"807_CR9","first-page":"1220","volume":"96","author":"K Yilmaz","year":"2007","unstructured":"Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N (2007) Bone mineral density in children with neurofibromatosis 1. Acta Paediatr Oslo Nor 1992 96(8):1220\u20132","journal-title":"Acta Paediatr Oslo Nor 1992"},{"issue":"1","key":"807_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jpeds.2006.10.048","volume":"150","author":"DA Stevenson","year":"2007","unstructured":"Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC et al (2007) Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150(1):83\u201388","journal-title":"J Pediatr"},{"issue":"4","key":"807_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/01.bpb.0000271310.87997.ae","volume":"27","author":"S Dulai","year":"2007","unstructured":"Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG (2007) Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27(4):472\u2013475","journal-title":"J Pediatr Orthop"},{"issue":"9","key":"807_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00198-005-1940-2","volume":"16","author":"M Lammert","year":"2005","unstructured":"Lammert M, Kappler M, Mautner V-F, Lammert K, St\u00f6rkel S, Friedman JM et al (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 16(9):1161\u20131166","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"issue":"4","key":"807_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/jmg.2008.061895","volume":"46","author":"T Tucker","year":"2009","unstructured":"Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse H-P et al (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46(4):259\u2013265","journal-title":"J Med Genet"},{"issue":"11","key":"807_CR14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/jbmr.1685","volume":"27","author":"E Heerv\u00e4","year":"2012","unstructured":"Heerv\u00e4 E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, Aro HT et al (2012) A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 27(11):2333\u20132337","journal-title":"J Bone Miner Res"},{"issue":"1","key":"807_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00223-012-9661-y","volume":"92","author":"E Heerv\u00e4","year":"2013","unstructured":"Heerv\u00e4 E, Leinonen P, Kuorilehto T, Peltonen S, P\u00f6yh\u00f6nen M, V\u00e4\u00e4n\u00e4nen K et al (2013) Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years. Calcif Tissue Int 92(1):23\u201327","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"807_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.bone.2010.06.001","volume":"47","author":"E Heerv\u00e4","year":"2010","unstructured":"Heerv\u00e4 E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, V\u00e4\u00e4n\u00e4nen K et al (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47(3):583\u2013590","journal-title":"Bone"},{"issue":"4","key":"807_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bone.2007.11.006","volume":"42","author":"A Schindeler","year":"2008","unstructured":"Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42(4):616\u2013622","journal-title":"Bone"},{"issue":"1","key":"807_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00198-009-0933-y","volume":"21","author":"S Seitz","year":"2010","unstructured":"Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE et al (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21(1):119\u2013127","journal-title":"Osteoporos Int"},{"issue":"1","key":"807_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ymgme.2007.12.004","volume":"94","author":"N Brunetti-Pierri","year":"2008","unstructured":"Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M et al (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94(1):105\u2013111","journal-title":"Mol Genet Metab"},{"issue":"10","key":"807_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/jmg.2006.041095","volume":"43","author":"M Lammert","year":"2006","unstructured":"Lammert M, Friedman JM, Roth HJ, Friedrich RE, Kluwe L, Atkins D et al (2006) Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet 43(10):810\u2013813","journal-title":"J Med Genet"},{"issue":"4","key":"807_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00403-011-1191-3","volume":"304","author":"L Petramala","year":"2012","unstructured":"Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G et al (2012) Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 304(4):325\u2013331","journal-title":"Arch Dermatol Res"},{"issue":"7\u20138","key":"807_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.clinbiochem.2014.02.020","volume":"47","author":"C Schnabel","year":"2014","unstructured":"Schnabel C, Dahm S, Streichert T, Thierfelder W, Kluwe L, Mautner VF (2014) Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1. Clin Biochem 47(7\u20138):560\u2013563","journal-title":"Clin Biochem"},{"key":"807_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/402838","volume":"2015","author":"L Souza Mario Bueno","year":"2015","unstructured":"Souza Mario Bueno L, Rosset C, Aguiar E, Pereira F de S, Izetti Ribeiro P, Scalco R et al (2015) Vitamin D status and VDR genotype in NF1 patients: a case-control study from Southern Brazil. Int J Endocrinol 2015:1\u20139","journal-title":"Int J Endocrinol"},{"issue":"1","key":"807_CR24","first-page":"111","volume":"13","author":"CW Hockett","year":"2013","unstructured":"Hockett CW, Eelloo J, Huson SM, Roberts SA, Berry JL, Chaloner C et al (2013) Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1). J Musculoskelet Neuronal Interact 13(1):111\u2013119","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"3","key":"807_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jbspin.2012.07.010","volume":"80","author":"C Schnabel","year":"2013","unstructured":"Schnabel C, Jett K, Friedman JM, Frieling I, Kruse H-P, Mautner V (2013) Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Jt Bone Spine 80(3):315\u2013319","journal-title":"Jt Bone Spine"},{"issue":"2","key":"807_CR26","first-page":"99","volume":"58","author":"P Fardellone","year":"1991","unstructured":"Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C et al (1991) Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 58(2):99\u2013103","journal-title":"Rev Rhum Mal Osteoartic"},{"issue":"10","key":"807_CR27","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0755-4982(06)74847-3","volume":"35","author":"C Roux","year":"2006","unstructured":"Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S et al (2006) Traitement m\u00e9dicamenteux de l\u2019ost\u00e9oporose post-m\u00e9nopausique. Presse M\u00e9dicale 35(10):1529\u20131539","journal-title":"Presse M\u00e9dicale"},{"issue":"Pt B","key":"807_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cca.2015.09.021","volume":"451","author":"J-C Souberbielle","year":"2015","unstructured":"Souberbielle J-C, Cavalier E, Delanaye P, Massart C, Brailly-Tabard S, Cormier C et al (2015) Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations. Clin Chim Acta Int J Clin Chem 451(Pt B):149\u2013153","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"10","key":"807_CR29","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00198-008-0689-9","volume":"19","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL et al (2008) Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 19(10):1369\u20131378","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"issue":"7","key":"807_CR30","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res Off J Am Soc Bone Miner Res 11(7):984\u2013996","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"7","key":"807_CR31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1346-8138.13218","volume":"43","author":"M Koga","year":"2016","unstructured":"Koga M, Yoshida Y, Imafuku S (2016) Nutritional, muscular and metabolic characteristics in patients with neurofibromatosis type 1. J Dermatol 43(7):799\u2013803","journal-title":"J Dermatol"},{"key":"807_CR32","unstructured":"Chiffres du tabac\/Vos questions\/Nos reponses\/Accueil-tabac-info-service.fr [Internet]. [cited 2020 Sep 4]. https:\/\/www.tabac-info-service.fr\/Vos-questions-Nos-reponses\/Chiffres-du-tabac"},{"issue":"1","key":"807_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0971-3026.150155","volume":"25","author":"A Gupta","year":"2015","unstructured":"Gupta A, Dwivedi A, Patel P, Gupta S (2015) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: case report and literature review. Indian J Radiol Imaging 25(1):63\u201366","journal-title":"Indian J Radiol Imaging"},{"issue":"5","key":"807_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/00000441-199105000-00006","volume":"301","author":"K Konishi","year":"1991","unstructured":"Konishi K, Nakamura M, Yamakawa H, Suzuki H, Saruta T, Hanaoka H et al (1991) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 301(5):322\u2013328","journal-title":"Am J Med Sci"},{"issue":"14","key":"807_CR35","first-page":"7","volume":"1","author":"J-C Souberbielle","year":"2016","unstructured":"Souberbielle J-C (2016) Epidemiology of vitamin-D deficiency. Geriatr Psychol Neuropsychiatr Vieil 1(14):7\u201315","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"issue":"6","key":"807_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1203\/PDR.0b013e31816fee45","volume":"63","author":"DA Stevenson","year":"2008","unstructured":"Stevenson DA, Schwarz EL, Viskochil DH, Moyer-Mileur LJ, Murray M, Firth SD et al (2008) Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res 63(6):697\u2013701","journal-title":"Pediatr Res"},{"issue":"6","key":"807_CR37","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s00223-013-9835-2","volume":"94","author":"E Heerv\u00e4","year":"2014","unstructured":"Heerv\u00e4 E, Huilaja L, Leinonen P, Peltonen S, Peltonen J (2014) Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. Calcif Tissue Int 94(6):608\u2013612","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"807_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1179\/2295333714Y.0000000094","volume":"70","author":"IC Benlidayi","year":"2015","unstructured":"Benlidayi IC, Ortac EA, Kozanoglu E (2015) Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine. Acta Clin Belg 70(2):130\u2013132","journal-title":"Acta Clin Belg"},{"issue":"3","key":"807_CR39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bone.2011.12.011","volume":"50","author":"E Heerv\u00e4","year":"2012","unstructured":"Heerv\u00e4 E, Peltonen S, Svedstr\u00f6m E, Aro HT, V\u00e4\u00e4n\u00e4nen K, Peltonen J (2012) Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone 50(3):798\u2013803","journal-title":"Bone"},{"key":"807_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s11689-017-9198-5","volume":"9","author":"AB Rietman","year":"2017","unstructured":"Rietman AB, Oostenbrink R, Bongers S, Gaukema E, van Abeelen S, Hendriksen JG et al (2017) Motor problems in children with neurofibromatosis type 1. J Neurodev Disord 9:19","journal-title":"J Neurodev Disord"},{"issue":"4","key":"807_CR41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/hmg\/ddx423","volume":"27","author":"MA Summers","year":"2018","unstructured":"Summers MA, Rupasinghe T, Vasiljevski ER, Evesson FJ, Mikulec K, Peacock L et al (2018) Dietary intervention rescues myopathy associated with neurofibromatosis type 1. Hum Mol Genet 27(4):577\u201388","journal-title":"Hum Mol Genet"},{"issue":"10","key":"807_CR42","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/ajmg.a.33045","volume":"149A","author":"F Elefteriou","year":"2009","unstructured":"Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK et al (2009) Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 149A(10):2327\u20132338","journal-title":"Am J Med Genet A"},{"key":"807_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.yebeh.2017.05.011","volume":"73","author":"A Pecoraro","year":"2017","unstructured":"Pecoraro A, Arehart E, Gallentine W, Radtke R, Smith E, Pizoli C et al (2017) Epilepsy in neurofibromatosis type 1. Epilepsy Behav EB 73:137\u2013141","journal-title":"Epilepsy Behav EB"},{"issue":"10","key":"807_CR44","first-page":"851","volume":"13","author":"B Abdolrahimzadeh","year":"2016","unstructured":"Abdolrahimzadeh B, Piraino DC, Albanese G, Cruciani F, Rahimi S (2016) Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography. Clin Ophthalmol Auckl NZ 13(10):851\u2013860","journal-title":"Clin Ophthalmol Auckl NZ"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-021-00807-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T18:04:01Z","timestamp":1667066641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-021-00807-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s00223-021-00807-6","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"9 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Maud Jalabert, Salah Ferkal, Arthur Mageau, Laurence Allanore, Philippe Le Corvoisier, Florent Eymard, Emilie Sbidian declare that they have no conflict of interest. Xavier Chevalier declare he have conflict of interest with IBSA, Flexion Therapics, Pfizer, Sanofi and Nordic Pharma. Pierre Wolkenstein declare he have conflict of interest with AstraZeneca, Springworks, Laboratoire d\u2019Uriage, Pierre Fabre Dermatologie. J.C. Souberbielle declare he have conflict of interest with DiaSorin, Roche diagnostics, Mylan, MSD, Lily, Effik, Iprad Pharma, Yoplait.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"All animal procedures were approved by the national French ethical committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}